Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Intestinal TM6SF2 Protects Against Metabolic Dysfunction-associated Steatohepatitis through the Gut-Liver Axis

ABSTRACT:

Transmembrane-6 superfamily member 2 (TM6SF2) regulates hepatic fat metabolism and is closely associated with metabolic dysfunction-associated steatohepatitis (MASH). MASH involves genetic predisposition and gut microbiota alteration, yet the role of host-microbes interaction in disease development remains unclear. Here, we discover that mice with Tm6sf2 specific knockout in intestinal epithelial cells (Tm6sf2ΔIEC) developed MASH, accompanied by impaired intestinal barrier and microbial dysbiosis. Transplanting stools from Tm6sf2ΔIEC mice induce steatohepatitis in recipient germ-free mice, whereas MASH is alleviated in Tm6sf2ΔIEC mice cohoused with wildtype mice. Mechanistically, Tm6sf2-deficient intestinal cells secrete increased free fatty acids by interplaying with fatty acid-binding protein 5 to induce intestinal barrier dysfunction, pathobiont enrichment and elevated lysophosphatidic acid (LPA). LPA is further translocated to the liver, causing lipid accumulation and inflammation. Pharmacological inhibition of LPA receptor suppresses MASH in both Tm6sf2ΔIEC and wildtype mice. Hence, modulating microbiota or blocking metabolite receptor is potential therapeutics against TM6SF2 deficiency-induced MASH.

INSTRUMENT(S): Liquid Chromatography MS - alternating - reverse phase

PROVIDER: MTBLS11004 | MetaboLights | 2024-10-08

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	X19.raw	Raw
	X20.raw	Raw
	X21.raw	Raw
	X22.raw	Raw
	X23.raw	Raw

Items per page:

1 - 5 of 43

Similar Datasets

DIO-MASH mice analysed for hepatic gene expression after treatment with semaglutide

Project description:Modulation of metabolic, inflammatory, and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. We show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation, and reduced hepatic expression of fibrosis- and inflammation-related gene pathways.

2025-04-25 | GSE294629 | GEO

Project description:Microbome of Metabolic dysfunction-associated steatohepatitis (MASH) Mice

| PRJNA1247707 | ENA

Proteomic Analysis of Hepatic Fbp1 Deficiency in Mouse Models

Project description:Data from study comparing liver tissue of mice deficient of hepatic Fbp1. Lack of Fbp1 reveals Fbp1 and NRF2 as important protein regulations in metabolic dysfunction-associated steatohepatitis (MASH).

2024-08-19 | MSV000095646 | MassIVE

Characteristics of liver tissues of MASH compared to those of Simple Steatosis mice.

Project description:Characteristics of hepatocytes of Metabolic Dysfunction-Associated Steatohepatitis (MASH) mice were compared compared to those of Simple Steatosis (SS) mice in the context of UPR response.

2025-06-19 | GSE296715 | GEO

Duodenal-derived organoids from MASH patients exhibit altered digestive homeostasis.

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive disease linked to conditions like fibrosis, cirrhosis, and liver cancer, often resulting in higher mortality rates, primarily due to cardiovascular events. While MASH is closely tied to metabolic syndrome, recent research underscores the importance of the gut-liver axis in its pathogenesis, an aspect less explored in human studies. To address this gap, duodenal epithelial organoids were generated from both MASH and healthy (controls) subjects. Organoid formation efficiency was similar between controls derived epithelial organoids (CDEOs) and MASH derived epithelial organoids (MDEOs) groups. Variability in growth patterns was observed, with MDEOs frequently exhibiting cystic spheroid morphology. MASH-derived organoids displayed altered homeostasis and digestive potential in the duodenal epithelium. Despite potential lineage bias, MDEOs retained their lipid metabolic capacity, possibly mediated by lipid oxidation in stem/progenitor cells. Notably, cell adhesion components were misexpressed in MASH-derived organoids, indicating significant intrinsic alterations in cell-cell adhesion potential compared to controls. However, MDEOs maintained transepithelial electric resistance and leak pathway integrity, indicating that the intestinal epithelial barrier remained functionally intact in MDEOs under tested conditions. This study sheds light on the intricate dynamics of duodenal epithelial alterations in MASH, highlighting potential therapeutic avenues for restoring intestinal homeostasis.

2024-12-13 | GSE268518 | GEO

Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis

Project description:We explore whether a low-energy diet intervention for Metabolic dysfunction-associated steatohepatitis (MASH) improves liver disease by means of modulating the gut microbiome. 16 individuals were given a low-energy diet (880 kcal, consisting of bars, soups, and shakes) for 12 weeks, followed by a stepped re-introduction to whole for an additional 12 weeks. Stool samples were obtained at 0, 12, and 24 weeks for microbiome analysis. Fecal microbiome were measured using 16S rRNA gene sequencing. Positive control (Zymo DNA standard D6305) and negative control (PBS extraction) were included in the sequencing. We found that low-energy diet improved MASH disease without lasting alterations to the gut microbiome.

2024-12-31 | E-MTAB-14061 | biostudies-arrayexpress

Transciptome profile of liver tissues from CD163KO mice after 8 weeks of Western diet.

Project description:Liver macrophages have a high expression of the macrophage-specific scavenger receptor CD163 but during metabolic dysfunction-associated steatohepatitis (MASH) development CD163 undergoes increased shedding and downregulated expression in the liver in humans. Herein, we derived a hepatic-transcriptome based dataset to understand the development of early hepatic steatosis in CD163 knockout mice and their littermate controls.

2025-10-01 | GSE305484 | GEO

CDA HFD mice analysed for hepatic gene expression after treatment with semaglutide

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying signals and pathways driving semaglutide-induced MASH resolution are not well understood. We show that, in two preclinical MASH models, semaglutide improved histological markers of fibrosis and inflammation, and reduced hepatic expression of fibrosis- and inflammation-related gene pathways. NOTE: dose is 20 µg/kg QD as stated in the publication, not 10 nmol/kg as stated in the fastq file names!

2025-04-25 | GSE294630 | GEO

Circadian disruption exacerbates MASH in mice by reducing intestinal Akkermansia muciniphila abundance via the FXR-CYP7A1-bile acid axis_Targeting Bile Acids

Project description:<p>Circadian disruption has emerged as a significant public health issue and is increasingly recognized as a contributor to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), though the underlying mechanisms remain poorly understood. In this study, we established a mouse model combining continuous light exposure and a western diet to investigate how circadian disruption exacerbates metabolic dysfunction-associated steatohepatitis (MASH). Our results demonstrated that circadian disturbance aggravated hepatic inflammation, lipid accumulation, and intestinal barrier impairment. Through integrated 16S rRNA sequencing and metabolomic analyses, we identified a marked reduction in Akkermansia muciniphila abundance and an elevation in CDCA-3S. Supplementation with A. muciniphila, taurine, or the FXR agonist obeticholic acid restored microbial and metabolic homeostasis, subsequently alleviating MASH pathology. Mechanistically, our data suggest these beneficial effects may involve the FXR–CYP7A1 signaling pathway. Our findings indicate that circadian disruption aggravates MASH potentially through reducing A. muciniphila abundance in a process associated with the FXR–CYP7A1–bile acid axis , and highlight the potential of microbial and metabolic interventions as novel therapeutic strategies for individuals with sleep-related circadian disorders.</p>

2026-02-05 | MTBLS13845 | MetaboLights

Circadian disruption exacerbates MASH in mice by reducing intestinal Akkermansia muciniphila abundance via the FXR-CYP7A1-bile acid axis_Targeting Bile Acids_Untargeted Serum Metabolomics

2026-02-05 | MTBLS13848 | MetaboLights